45 WIGGINS AVENUE, BEDFORD, MA
News, Legal Opinion
Announces Second Quarter 2026 Financial Results and Provides Business Updates
Announces Completion of Enrollment of 162 Patients into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Election of Directors at Stoke Therapeutics' 2026 Annual Meeting
Announces First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics Dismisses KPMG as Independent Auditor
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Direct Registration System
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Correspondence
Submission Upload